Skip to content

Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status

Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04556513
Acronym
RECOVIDS
Enrollment
543
Registered
2020-09-21
Start date
2020-09-18
Completion date
2022-09-07
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ARDS, Covid19, Functional Recovery

Brief summary

In this study, the investigators are attempting to evaluate the influence of socio-economic factors on the functional recovery (physical and psychological) of patients who developed ARDS after a COVID-19 infection, with the aim of offering personalized medical and social follow-up and support measures in order to avoid medium- and long-term complications, which can result in handicaps, reduced quality of life, and a higher risk of death.

Interventions

OTHERParaclinical examination

Respiratory functional tests

OTHERClinical Examination

Clinical Examination

OTHERquality of life questionnaires

SF36, VSRQ, IESR, HADS

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Inpatient in ICU for PCR-proven SARS-VOC-2 infection regardless of specimen type * Patient who received a chest CT scan in the initial phase of management (either just before or during hospitalization in the intensive care unit) * Patient who has received invasive or non-invasive ventilatory support, or humidified and heated high-flow oxygen (HFO). * ARDS meeting the criteria of the 2012 Berlin definition. For patients who have received only HFO, a flow rate at least equal to 50L/minute with a FiO2 strictly greater than 50% with a PaO2/FiO2 ratio less than or equal to 200 will be required for inclusion. * Patient who gave oral consent after being informed about the conduct of this study.

Exclusion criteria

* Patient with limited autonomy prior to hospitalization in limited intensive care unit: walking distance of less than 50 meters, WHO classification status 3 and 4. * Patient with a history of chronic respiratory failure as defined by the use of long-term oxygen therapy or non-invasive home ventilation, excluding patients with SAS and/or hypoventilation obesity syndrome. * Patient with a history of central or peripheral neurological conditions limiting the patient's motor autonomy and the performance on gait tests or Pulmonary function Tests * Patient refusing to participate * Patient \< 18 years of age * Patient not affiliated or not benefiting from national health insurance * Patient under guardianship, curatorship or protected adult * Patient unable to understand and consent to the research protocol SECONDARY

Design outcomes

Primary

MeasureTime frameDescription
Respiratory sequelae 6 months after resuscitation.Through study completion, an average of 6 monthsDefined by the presence of at least one of the following : * An alteration of the alveolar-capillary diffusion of CO \<80% of the predicted normal values * And/or a forced vital capacity \<80% of predicted normal values * and/or O2 desaturation in the 6-minute walk test * And/or pulmonary parenchymatous disease with fibrosis in tomodensitometry.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026